Published in J Clin Oncol on September 15, 2000
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging (2007) 2.23
Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg (2004) 1.87
Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer (2008) 1.69
Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging (2006) 1.67
Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging (2011) 1.58
Impact of FDG-PET for staging of oesophageal cancer. Langenbecks Arch Surg (2004) 1.42
The use of "overall accuracy" to evaluate the validity of screening or diagnostic tests. J Gen Intern Med (2004) 1.41
Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer (2006) 1.33
Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res (2007) 1.18
Pre-clinical evaluation of fluorescent deoxyglucose as a topical contrast agent for the detection of Barrett's-associated neoplasia during confocal imaging. Technol Cancer Res Treat (2011) 1.10
18F-FDG PET/CT imaging in oncology. Ann Saudi Med (2011) 1.08
Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res (2009) 1.04
Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol (2011) 0.99
18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol (2007) 0.97
The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol (2010) 0.93
The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. Gastrointest Cancer Res (2008) 0.93
FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol (2011) 0.92
Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. Eur Radiol (2010) 0.92
Metastases of esophageal carcinoma to skeletal muscle: single center experience. World J Gastroenterol (2012) 0.91
The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging (2005) 0.91
The role of positron emission tomography in esophageal cancer. Gastrointest Cancer Res (2008) 0.89
A suspected [18F]fluorodeoxyglucose positron emission tomography-negative metastatic lymph node successfully diagnosed by laparoscopic staging in esophageal cancer: report of two cases. Surg Today (2009) 0.87
Technological advances in radiotherapy for esophageal cancer. World J Gastroenterol (2010) 0.86
18F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography: Computed Tomography for Preoperative Staging in Gastric Cancer Patients. J Gastric Cancer (2012) 0.86
Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based and pathological findings. Int J Clin Oncol (2009) 0.84
Clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy. World J Gastroenterol (2009) 0.84
The impact of functional imaging on radiation medicine. Radiat Oncol (2008) 0.84
Appraisal of staging endoscopic ultrasonography in a modern high-volume esophageal program. World J Surg (2013) 0.83
Role of F18-FDG PET/CT in the Staging and Restaging of Esophageal Cancer: A Comparison with CECT. Indian J Surg Oncol (2012) 0.82
FDG-PET uptake in occult acute pelvic fracture. Skeletal Radiol (2003) 0.81
18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut (2003) 0.81
Positron Emission Tomography's Utility in Esophageal Cancer Management. J Thorac Dis (2009) 0.81
Relationship between (18)F-fluorodeoxyglucose uptake in primary lesions and clinicopathological characteristics of esophageal squamous cell carcinoma patients. Exp Ther Med (2012) 0.80
The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging (2006) 0.80
Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer. Br J Cancer (2014) 0.80
Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy. Int J Clin Exp Med (2015) 0.79
Detection of lymph node metastases with ultrasmall superparamagnetic iron oxide (USPIO)-enhanced magnetic resonance imaging in oesophageal cancer: a feasibility study. Cancer Imaging (2009) 0.79
Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. Front Oncol (2016) 0.78
Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites? Eur J Nucl Med Mol Imaging (2007) 0.78
Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation. World J Surg Oncol (2007) 0.78
Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers. Int J Mol Imaging (2012) 0.78
Positron emission tomography: another useful test for staging esophageal cancer. J Clin Oncol (2000) 0.77
Solitary Psoas Muscle Metastasis of Gastroesphageal Junction Adenocarcinoma. Iran J Pathol (2016) 0.77
Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg (2003) 0.77
Clinical significance of incidental findings on staging positron emission tomography for oesophagogastric malignancies. Ann R Coll Surg Engl (2014) 0.77
PET scans as a predictive marker of survival in advanced colorectal cancer. Clin Colorectal Cancer (2014) 0.77
Potential impact of (18)FDG-PET/CT on surgical approach for operable squamous cell cancer of middle-to-lower esophagus. Onco Targets Ther (2016) 0.76
Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer. Gastrointest Cancer Res (2011) 0.76
Incorporating PET information in radiation therapy planning. Biomed Imaging Interv J (2007) 0.76
Comparison of uptake characteristics and prognostic value of 201Tl and 18F-FDG in esophageal cancer. World J Surg (2008) 0.75
Radiologist experience and CT examination quality determine metastasis detection in patients with esophageal or gastric cardia cancer. Eur Radiol (2008) 0.75
Management of oesophageal cancer. Indian J Surg (2010) 0.75
Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation. Transl Oncol (2017) 0.75
The 100 most cited articles investigating the radiological staging of oesophageal and junctional cancer: a bibliometric analysis. Insights Imaging (2016) 0.75
Comment on the publication 'Impact of FDG-PET for staging of oesophageal cancer' by A. Imdahl et al. Langenbecks Arch Surg (2005) 0.75
The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. Gastroenterol Clin North Am (2009) 0.75
A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers. HPB (Oxford) (2015) 0.75
Positron emission tomography for initial staging of esophageal cancer among medicare beneficiaries. J Gastrointest Oncol (2016) 0.75
Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol (2017) 0.75
8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg (2017) 0.75
Pre-Chemoradiotherapy FDG PET/CT cannot Identify Residual Metabolically-Active Volumes within Individual Esophageal Tumors. J Nucl Med Radiat Ther (2015) 0.75
Positron emission tomography in esophageal cancer. Gastrointest Cancer Res (2008) 0.75
Endoscopic ultrasonography (EUS) in the staging of malignancy. Cancer Imaging (2004) 0.75
Imaging of hypopharyngeal and cervical oesophageal cancer. Cancer Imaging (2003) 0.75
Patients' perception of diagnostic tests in the preoperative assessment of esophageal cancer. Patient Prefer Adherence (2008) 0.75
Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis. Strahlenther Onkol (2017) 0.75
A case of a superficial carcinoma of the esophagus with isolated lymph node metastasis around the abdominal aorta. Surg Today (2012) 0.75
Immediate preoperative laparoscopic staging for squamous cell carcinoma of the esophagus. Surg Endosc (2005) 0.75
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature (1999) 10.97
HIV-1 nomenclature proposal. Science (2000) 6.61
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Passage of inhaled particles into the blood circulation in humans. Circulation (2002) 5.97
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (2007) 5.68
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet (1991) 5.02
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS (1993) 3.52
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology (1995) 3.44
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol (2001) 3.21
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer (2003) 2.97
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol (2005) 2.88
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol (2002) 2.86
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol (2005) 2.84
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Appendectomy protects against ulcerative colitis. Gastroenterology (1994) 2.71
Microscopic colitis with giant cells. Histopathology (2002) 2.64
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol (2002) 2.60
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology (1999) 2.46
Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg (1992) 2.43
Dissociation of cardiomyocyte apoptosis and dedifferentiation in infarct border zones. Eur Heart J (2002) 2.41
Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology (2001) 2.41
Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol (1999) 2.30
Endoscopic injection therapy to prevent rebleeding from peptic ulcers with a protruding vessel: a controlled comparative trial. Gut (1993) 2.25
Human immunodeficiency virus. Phylogeny and the origin of HIV-1. Nature (2001) 2.20
Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) (2006) 2.17
Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg (2003) 2.15
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 2.10
An iterative maximum-likelihood polychromatic algorithm for CT. IEEE Trans Med Imaging (2001) 2.09
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology (1996) 2.08
Changing antibiotic susceptibility of Neisseria gonorrhoeae in Franceville, Gabon. Antimicrob Agents Chemother (1987) 2.02
Polymerase chain reaction assay for pertussis: simultaneous detection and discrimination of Bordetella pertussis and Bordetella parapertussis. J Clin Microbiol (1993) 1.95
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol (2009) 1.93
Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee. Virology (1996) 1.91
Collagenous colitis: an unrecognised entity. Gut (1980) 1.90
Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int (2006) 1.89
Characterization of a novel simian immunodeficiency virus from guereza colobus monkeys (Colobus guereza) in Cameroon: a new lineage in the nonhuman primate lentivirus family. J Virol (2001) 1.81
In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1984) 1.80
Dynamics of the population structure of Bordetella pertussis as measured by IS1002-associated RFLP: comparison of pre- and post-vaccination strains and global distribution. Microbiology (1996) 1.79
Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. FASEB J (2000) 1.78
Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Med Virol (1996) 1.77
In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology (1998) 1.74
Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol (2009) 1.72
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr (2001) 1.71
Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol (2000) 1.70
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer (2004) 1.70
Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol (1997) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver (1998) 1.67
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.67
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol (2012) 1.61
Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. Philos Trans R Soc Lond B Biol Sci (2001) 1.61
In-vitro activity of Ro-15-8074, a new oral cephalosporin. J Antimicrob Chemother (1985) 1.59
The differentiation of Bordetella parapertussis and Bordetella bronchiseptica from humans and animals as determined by DNA polymorphism mediated by two different insertion sequence elements suggests their phylogenetic relationship. Int J Syst Bacteriol (1996) 1.58
Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis (1981) 1.58
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol (2007) 1.58